PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

2024-520138-31-00 · tracked via the Priya Life Science EU tracker

Sponsor

University Of Cologne

Sponsor type

Educational Institution

Therapeutic area

Neoplasms

Decision date

10/02/2026

Enrollment target

Sites

Germany

Condition studied

Early-stage favorable classic Hodgkin lymphoma

Investigational medicinal product(s)

KEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Progression-free survival (PFS) at 1 year

Endpoint detail

Remission status after pembrolizumab therapy and after consolidation Radiotherapy, Progression-free survival (PFS) at 2 years, Overall survival (OS) at 1 year and at 2 years, Adverse events during and after anti-PD-1 therapy, Patient-reported outcomes at baseline, during treatment and during follow-up, Rate of early discontinuation of trial treatment, Rate and types of HL-directed treatment administered in addition to trial treatment, Event-free survival (EFS) at 1 year and at 2 years

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520138-31-00 on CTIS ↗ ← All trials in the EU